Tag: bioequivalence standards

FDA Bioequivalence Standards for NTI Drugs: Special Requirements Explained

Jan, 8 2026| 15 Comments

The FDA enforces stricter bioequivalence standards for narrow therapeutic index (NTI) drugs like warfarin, digoxin, and phenytoin, requiring tighter limits (90-111%) and replicate studies to ensure patient safety. These rules prevent dangerous fluctuations in blood levels that can occur with generics.

Crossover Trial Design: How Bioequivalence Studies Are Structured

Dec, 10 2025| 12 Comments

Crossover trial designs are the gold standard for bioequivalence studies, using each participant as their own control to reduce variability and sample size. Learn how AB/BA and replicate designs work, when to use them, and what regulators require.